Dr. Tin-Chuen Yeung is currently the Managing Director of Everest Intellectual Property Law Group, which he co-founded in April, 2004. He is responsible for the day-to-day operations of the firm as well as patent prosecution for his clients. He concentrates his practice in patent prosecution and intellectual property strategy counseling, particularly in biotechnology, pharmaceuticals, bioinformatics, nanotechnology, medical devices and wireless communications technology.

In his previous position as Head of Strategic Development of Life Sciences with the Chicago law firm of Bell, Boyd, and Lloyd, LLC, he was with the intellectual property group responsible for patent prosecution and client development in life sciences. He was the Vice Chair of the Biotechnology Committee of the Intellectual Property Law Association of Chicago. Before joining Bell Boyd & Lloyd, he was with the Chicago intellectual property law firm Wallenstein & Wagner, Ltd. Prior to that, Dr. Yeung served as President of Everest International, Inc., a consultant to Fortune 500 medical technology companies and start-up biotechnology companies. He has also served as Director of Strategy and Business Development for the Biosciences Division at Baxter International Inc., where he managed the strategy for world-wide development, marketing and manufacturing of recombinant protein products. He also served as Director of Corporate Development for Baxter responsible for management of Baxter’s acquisitions, technology commercialization, licensing and strategic alliances. Prior to his career in industry, Dr. Yeung was a Research Fellow in clinical pharmacology at Harvard Medical School. He also serves on the advisory boards of several companies.

Dr. Yeung holds a BS degree in Biochemistry and a PhD in pharmacology from the State University of New York, as well as a Master of Management from Kellogg Graduate School of Management, Northwestern University.